ArticleDrug and alcohol review2026
Experiences of People Who Discontinue Long-Acting Injectable Buprenorphine Treatment Recently Released From Prison in New South Wales, Australia.
Article in Drug and alcohol review, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
introductionAmong other benefits, opioid agonist treatment (OAT; methadone and buprenorphine) is protective against overdose for people with opioid use disorder following release from custody. Long-acting injectable buprenorphine (LAIB) is safe with an apparent low risk of diversion relative to other OAT formulations in correctional settings and may become a preferred OAT formulation in this setting. Factors that influence retention in LAIB post-release are unknown.
methodPeople receiving LAIB in nine New South Wales prisons were consented to participate in a survey designed to explore treatment experiences post-release. Participants who reported ceasing LAIB within 12 weeks of release were invited to complete an in-depth interview using a semi-structured guide via phone or secure videoconference in the community, or in custody if reincarcerated. Interviews were transcribed verbatim, and data analysed using iterative categorisation and thematic analysis.
resultsA total of 31 participants who ceased LAIB within 12 weeks following release from custody were interviewed. Mean age was 34 years (SD 9), 24 were male and 16 identified as Aboriginal People. Key themes regarding treatment cessation were misinformation and lack of treatment education, limited transition supports for housing, mental health and illicit substance use, and changing treatment benefits between the custody and community contexts including illicit substance preferences and side effects. DISCUSSION AND
conclusionsNumerous personal experiences and psychosocial factors impacted participant motivations and capacity to continue LAIB post-release. Understanding and addressing these factors is necessary to support treatment retention and increase community-based program acceptability and continuation in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.